Establishment and characterization of a new activated B-cell-like DLBCL cell line, TMD12

• Published in: Experimental hematology 2022-12, Vol.116, p.37-49
• Main Authors: Nagao, Toshikage, Yoshifuji, Kota, Sadato, Daichi, Motomura, Yotaro, Saito, Makiko, Yamamoto, Kurara, Yamamoto, Kouhei, Nogami, Ayako
• Format: Article
• Language: English
• Subjects: B-Lymphocytes - metabolism; Cell Line; Cell Line, Tumor; Humans; Lymphoma, Large B-Cell, Diffuse - drug therapy; Lymphoma, Large B-Cell, Diffuse - genetics; Lymphoma, Large B-Cell, Diffuse - metabolism; Myeloid Differentiation Factor 88 - genetics; Myeloid Differentiation Factor 88 - metabolism; Neoplasm Recurrence, Local
• ISSN: 0301-472X; 1873-2399
• DOI: 10.1016/j.exphem.2022.09.005

•A novel diffuse large B-cell lymphoma (DLBCL) cell line, designated as TMD12, was established and characterized.•TMD12 cells displayed constitutive activation of the nuclear factor κB pathway because of mutations in MYD88 and CD79B, indicating an activated B-cell-like (ABC) subtype.•Oncogenic activation of the tumor progression locus 2-p105 pathway might be involved in the tumorigenesis of ABC-DLBCL. We report the establishment of a novel activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL) cell line, designated as TMD12, from a patient with highly refractory DLBCL. ABC-DLBCL is a subtype with a relatively unfavorable prognosis that was originally categorized using gene expression profiling according to its cell of origin. TMD12 cells were isolated from the pleural effusion of the patient at relapse and passaged continuously in vitro for >4 years. The cells displayed cluster of differentiation (CD)19, CD20, CD22, CD38, human leukocyte antigen-DR isotype, and κ positivity and CD5, CD10, CD23, and λ negativity, as detected using flow cytometric analysis. The chromosomal karyotypic analysis, including the spectral karyotyping method, confirmed t(1;19)(q21:q13.1), del(6q23), gain of chromosome 18, and other abnormalities. Mutation analyses, including whole-exome sequencing, revealed that TMD12 cells harbored mutations in MYD88 and CD79B, indicating an ABC subtype. TMD12 cells exhibited chronic active B-cell receptor signaling and constitutive activation of the nuclear factor κB pathway, which is typically associated with sensitivity to a specific Bruton tyrosine kinase inhibitor, ibrutinib. Intriguingly, TMD12 cells displayed moderate resistance to ibrutinib and lacked activation of Janus kinase/signal transducers and activators of transcription 3 signaling, another hallmark of this DLBCL subtype. Treatment with an inhibitor against tumor progression locus 2 (TPL2), a multifunctional intracellular kinase that is activated particularly downstream of Toll-like receptors or MYD88 and IκB kinase α/β (IKKα/β), suppressed the proliferation of TMD12 cells, implying the possible involvement of the TPL2-p105 pathway in the tumorigenesis of ABC-DLBCL. Because only a limited number of ABC-DLBCL cell lines are currently available, TMD12 cells might provide a useful tool in the search for novel druggable targets for this intractable lymphoma.